Latest from The US Oncology Network

Jeff Sharman, MD, discusses the question of BTK inhibitors in treating patients with chronic lymphocytic leukemia.
Jeff Sharman, MD, discusses the design of the phase III ELEVATE-TN trial in patients with previously untreated chronic lymphocytic leukemia.
Top researchers will present abstracts on latest clinical research advancing cancer treatment options.
Robert M. Rifkin, MD, attending physician, Rocky Mountain Cancer Centers, research lead, Multiple Myeloma, The US Oncology Network, discusses a trial looking at split dosing of daratumumab in myeloma.
The US Oncology Network has announced the results of the 2017 Merit-based Incentive Payment System for its affiliated practices.
Pressure to reduce costs associated with biologics is one of the forces driving the rapid expansion of biosimilars, which are biological drugs that are very similar to already approved reference biologics in terms of potency, safety, and efficacy.
Number One Rankings in 10 Key Performance Areas Reinforce McKesson Specialty Health’s Leading Position in the Oncology and Hematology Market
McKesson’s total solution streamlines MIPS reporting and provides access to custom quality measures, optimizing MIPS performance for community-based oncology practices
Publication Bottom Border
Border Publication